Activation of PGC-1α has been identified as a potential therapeutic target for the treatment and prevention of many age-related declines in physiological function, including insulin resistance [94], inflammation [92], and muscle atrophy (i.e., sarcopenia) [95]. The gene discussed is PPARGC1A; the disease is sarcopenia.